16:31 EDT Acrivon Therapeutics (ACRV) sees cash, equivalents funding expenses into 2Q27
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics assumed with an Overweight at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR
- Acrivon Therapeutics Reports Progress in Cancer Drug Development
- Acrivon Therapeutics Appoints New Chief Medical Officer
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue